News | Radiation Therapy | September 11, 2019

RadCalc 3D Monte Carlo Calculations for Photons Begins Beta Testing

Beta Testing begins of RadCalc 3Dmc version 7.1.1.0 utilizing Monte Carlo 3D dose volume QA technology

RadCalc 3D Monte Carlo Calculations for Photons Begins Beta Testing

September 11, 2019 — RadCalc version 7.1 with the Monte Carlo 3-D module has been released for beta testing to members of the beta testing team. The Monte Carlo 3D module utilizes technology acquired from the McGill University inventors. This release of RadCalc 3Dmc is the second of three 3D Dose Volume second check quality assurance (QA) packages. The completion of the beta test is anticipated in four weeks. An announcement of the final release date will be provided when available for purchase.

RadCalc 3Dmc utilizes the BeamNRC-based Monte Carlo dose calculation engine, providing independent, fast, easy and accurate 3-D dose volume verification for most commonly used treatment planning systems. The RadCalc 3Dmc beta release is compatible with Varian and Elekta machines. Support for additional radiotherapy treatment machines will be available in the near future.

Monte Carlo is widely recognized as the gold standard dose calculation method. The most challenging clinical cases involving highly heterogeneous structures are analyzed with the highest accuracy and confidence. Flexible implementation options allow users to combine the uncompromised accuracy of a Monte Carlo dose calculation algorithm with the levels of speed and productivity that allow busy radiation departments to meet their workflow needs.

RadCalc 3Dmc includes RadCalc AIR (Automated Import & Report) providing a fully automated process with percent difference, dose volume histogram (DVH), Gamma, and Distance to Agreement analysis tools. RadCalc 3Dmc’s fully automated process immediately alerts users to plans that fail to pass pre-set criteria.

RadCalc 3Dmc automatically checks whether DVH objectives are met for critical structures using both the treatment planning system (TPS) and RadCalc 3Dmc dose. Any number of DVH protocols can be loaded and be compared to one another from one analysis screen within RadCalc 3Dmc. Analysis reports are automatically attached to a verified plan and sent to a workstation via email or to a directory of choice on the server.

RadCalc 3Dmc is not yet available for sale in the United States. 

For more information: www.lap-laser.com

Related Content

Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.
News | Clinical Trials | February 03, 2020
February 3, 2020 — Melding the genetic and cellular analysis of tumors with how they appear in medical images could g
Elekta Unity MR Linac system
News | Radiation Oncology | January 30, 2020
January 30, 2020 — Elekta announced that it signed a contract wit